We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Medtech Mergers Could Break $100B Barrier this Year

Report: Medtech Mergers Could Break $100B Barrier this Year

August 28, 2015

During the first half of 2015, the total value of closed medtech mergers came in at $83 billion — a figure that tops some full-year figures from the past decade.

If this trend continues, the value of all mergers and acquisition deals in medtech could surpass $100 billion for the first year ever, according to a report from EP Vantage.

The report notes that there is no firm pattern in terms of M&A targets, with a range of technological areas involved. While the two biggest deals — Medtronic-Covidien and Zimmer-Biomet — involved scale and consolidation, many others saw companies entering new areas altogether. For example, Eurofins Scientific, which is active in food and pharmaceutical products testing, entered the in vitro testing arena when it bought Boston Heart Diagnostics.

For example, divestitures also propped up the numbers. Siemens took the fourth and fifth spots in terms of priciest deals with the sale of its hospital information technology business to Cerner for $2.7 billion and the shedding of its hearing aids product line to EQT Partners for $1.3 billion.

A Kinder FDA?

The report also notes that “a ray of sunshine” beamed from the FDA in terms of PMAs of HDEs — representing good news for innovation. The total number for both types of application approvals was 26 devices. If this trend continues, 2015 could be the best year for innovative medical devices coming to market since 2005. By way of comparison, there were 33 such approvals for all of 2014 — a 43 percent increase over 2013.

Approval times also are holding relatively steady. During the first half of 2015, the average approval time was 17.1 months, slightly off the 16.7 months for all of 2014. However, those numbers are better than the average 26.9 months for 2013.

The cardiology field saw 11 approvals — the same number for all of last year.

According to report, the faster FDA hasn’t been met with universal applause, citing a July 17 op-ed in The New York Times scolding the agency for allowing unsafe technologies on the market by adopting a more relaxed attitude toward clinical data.

“In some ways, it seems that the agency cannot win: the U.S. is widely believed to be more stringent than Europe in its assessment of medical devices, and efforts to tighten up European regulation have met with fierce resistance by industry lobbyists and patient groups,” the report’s authors write. They add that the two systems might meet in the middle, and companies could stop seeking CE mark certification before trying to enter the U.S. market.

Not all is rosy for the sector, however, as only $1.6 billion was raised in venture funding. The authors note that the first half of 2014 saw three rounds that exceeded $100 million. This year, no company has broken $60 million.

The half-year figures for initial public offerings remained fairly steady over the last half of 2014, with companies raising $705 million versus $723 million.

“With the huge and exciting changes that have gripped the industry over the past year having for the most part been brought to their respective conclusions, the sector seems to have attained a level of stability,” Elizabeth Cairns, EP Vantage medtech reporter and co-author of the report, says in a statement. “But start-ups are facing a worsening funding gap, and it will be crucial that this eases if a steady flow of safe and effective medical technologies is to be maintained.”

The report is available for download at www.evaluategroup.com/public/Reports/EPVantage-Medtech-HalfYear-Review-2015.aspx. — Elizabeth Hollis

Commercial Operations

Upcoming Events

  • 21Apr

    CDER’s Most Significant Guidance Priorities for 2021: Biosimilars/Biologics, Generics/Exclusivity, Real-World Evidence, Drug Development and Digital Health

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

  • 12May

    Extractables and Leachables: 101

  • 25May

    How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • EMA logo European Medicines Agency logo

    EMA Reviews GSK’s and Vir’s VIR-7831 for COVID-19

  • CE mark

    Hensler Surgical Technologies Earns CE Mark for Bone-Fusion Device

  • Eli lilly logo

    Eli Lilly Asks FDA to Nix EUA for Bamlanivimab Alone

  • CE mark

    Alimetry Earns CE Mark for Wearable Gastric Disease Diagnostic

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing